Author:
Njenga Sammy M.,Kanyi Henry M.,Mutungi Faith M.,Okoyo Collins,Matendechero Hadley S.,Pullan Rachel L.,Halliday Katherine E.,Brooker Simon J.,Wamae C. Njeri,Onsongo Joyce K.,Won Kimberly Y.
Funder
World Health Organization
Bill and Melinda Gates Foundation
DFID/MRC/Wellcome Trust global health trials scheme
Task Force for Global Health
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Parasitology
Reference40 articles.
1. WHO. Monitoring and epidemiological assessment of mass drug administration in the global program to eliminate lymphatic fi lariasis: a manual for national elimination programs. Geneva: World Health Organization; 2011.
2. Stolk WA, Swaminathan S, van Oortmarssen GJ, Das PK, Habbema JDF. Prospects for elimination of bancroftian filariasis by mass drug treatment in Pondicherry, India: a simulation study. J Infect Dis. 2003;188:1371–81.
3. Michael E, Malecela-Lazaro MN, Simonsen PE, Pedersen EM, Barker G, Kumar A, et al. Mathematical modelling and the control of lymphatic filariasis. Lancet Infect Dis. 2004;4:223–34.
4. Moraga P, Cano J, Baggaley RF, Gyapong JO, Njenga SM, Nikolay B, et al. Modelling the distribution and transmission intensity of lymphatic filariasis in sub-Saharan Africa prior to scaling up interventions: integrated use of geostatistical and mathematical modelling. Parasit Vectors. 2015;8:560.
5. Wijers DJ. Bancroftian filariasis in Kenya I. Prevalence survey among adult males in the Coast Province. Ann Trop Med Parasitol. 1977;71:313–31.